Lhasa Limited shared knowledge shared progress

Related pages

Related documents


This FAQs section details frequently asked questions about the ICH M7 guidelines. For FAQs on Lhasa products, please refer to the relevant product area.
Use the form below to search the ICH M7 for FAQs containing specific words or combinations of words.

Search for:
Why do I need to run in silico for impurities or degradants?

The draft ICH M7 guidelines on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, state that actual and potential impurities should be assessed for their mutagenic potential. The guidelines state that (Q)SAR methodologies can be used as part of this hazard assessment.

Potential impurities could include:

  • Starting materials and their contaminants
  • Reagents and catalysts
  • Solvents
  • Intermediates
  • Excipients and their contaminants
  • Leachables
  • Degradation products
Related questions

© 2018 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.